Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease
Top Cited Papers
- 19 January 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 121 (2), 221-229
- https://doi.org/10.1161/circulationaha.109.869008
Abstract
Background— Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial α4β2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown. Methods and Results— A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks. The primary end point was carbon monoxide-confirmed continuous abstinence rate for weeks 9 through 12 (last 4 weeks of treatment). The continuous abstinence rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 13.9%; odds ratio, 6.11; 95% confidence interval [CI], 4.18 to 8.93) and weeks 9 through 52 (19.2% versus 7....Keywords
This publication has 20 references indexed in Scilit:
- Varenicline for Tobacco DependenceNew England Journal of Medicine, 2008
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Nicotine receptor partial agonists for smoking cessationPublished by Wiley ,2007
- Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illnessAddiction, 2007
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Randomised controlled trial of smoking cessation intervention after admission for coronary heart diseaseBMJ, 2003
- The Safety of Transdermal Nicotine as an Aid to Smoking Cessation in Patients with Cardiac DiseaseNew England Journal of Medicine, 1996
- Task force 4. Efficacy of risk factor managementJournal of the American College of Cardiology, 1996
- Nicotine Replacement Therapy for Patients With Coronary Artery DiseaseArchives of Internal Medicine, 1994
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991